- Home
- PROK vs EBS Comparison
PROK vs EBS Comparison
Compare PROK & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- EBS
- Stock Information
- Founded
- PROK 2015
- EBS 1998
- Country
- PROK United States
- EBS United States
- Employees
- PROK N/A
- EBS N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- PROK Health Care
- EBS Health Care
- Exchange
- PROK Nasdaq
- EBS Nasdaq
- Market Cap
- PROK 334.8M
- EBS 359.3M
- IPO Year
- PROK N/A
- EBS 2006
- Fundamental
- Price
- PROK $2.45
- EBS $8.00
- Analyst Decision
- PROK Buy
- EBS Strong Buy
- Analyst Count
- PROK 5
- EBS 3
- Target Price
- PROK $6.25
- EBS $14.33
- AVG Volume (30 Days)
- PROK 2.4M
- EBS 964.3K
- Earning Date
- PROK 11-11-2025
- EBS 11-05-2025
- Dividend Yield
- PROK N/A
- EBS N/A
- EPS Growth
- PROK N/A
- EBS N/A
- EPS
- PROK N/A
- EBS 2.53
- Revenue
- PROK $527,000.00
- EBS $851,600,000.00
- Revenue This Year
- PROK $265.05
- EBS N/A
- Revenue Next Year
- PROK N/A
- EBS $19.24
- P/E Ratio
- PROK N/A
- EBS $3.16
- Revenue Growth
- PROK N/A
- EBS N/A
- 52 Week Low
- PROK $0.46
- EBS $4.02
- 52 Week High
- PROK $7.13
- EBS $12.73
- Technical
- Relative Strength Index (RSI)
- PROK 50.33
- EBS 48.99
- Support Level
- PROK $2.12
- EBS $7.45
- Resistance Level
- PROK $3.05
- EBS $8.62
- Average True Range (ATR)
- PROK 0.23
- EBS 0.41
- MACD
- PROK 0.03
- EBS -0.09
- Stochastic Oscillator
- PROK 35.48
- EBS 30.97
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.